Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul 7;26(25):3528-3541.
doi: 10.3748/wjg.v26.i25.3528.

Management of nonalcoholic fatty liver disease in the Middle East

Faisal M Sanai  1 , Faisal Abaalkhail  2 , Fuad Hasan  3 , Muhammad Hamed Farooqi  4 , Nawal Al Nahdi  5 , Zobair M Younossi  6
Affiliations
Review

Management of nonalcoholic fatty liver disease in the Middle East

Faisal M Sanai et al. World J Gastroenterol. .

Abstract

The prevalence of nonalcoholic fatty liver disease (NAFLD) in the Middle East is increasing in parallel to an increase in the prevalence of associated risk factors such as obesity, metabolic syndrome, and type 2 diabetes mellitus. About 20% to 30% of the patients progress to develop nonalcoholic steatohepatitis (NASH), a histological subtype of NAFLD, with features of hepatocyte injury such as hepatocyte ballooning. NASH can progress to fibrosis, cirrhosis, and even hepatocellular carcinoma. NAFLD thus causes a substantial burden on healthcare systems and it is imperative that appropriate strategies are discussed at a regional level to facilitate effective management tailored to the needs of the region. To fulfil this unmet need, expert gastroenterologists, hepatologists, and endocrinologists from the region came together in three advisory board meetings that were conducted in Saudi Arabia, United Arab Emirates, and Kuwait, to discuss current local challenges in NAFLD screening and diagnosis, and the different available management options. The experts discussed the disease burden of NAFLD/NASH in the Middle East; screening, diagnosis, and referral patterns in NAFLD; and available treatment options for NAFLD and NASH. This paper summarizes the discussions and opinion of the expert panel on the management of NAFLD/NASH and also presents an extensive literature review on the topic.

Keywords: Expert opinion; Middle East; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: None of the authors received any fees for writing this manuscript. Medical writing assistance was funded by Gilead Sciences. No other conflict is declared.

Figures

Figure 1
Figure 1
Basic algorithm for diagnosis and treatment of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. MetS: Metabolic syndrome; NAFL: Nonalcoholic fatty liver; NAFLD: Nonalcoholic fatty liver disease; NASH: Nonalcoholic steatohepatitis; T2DM: Type 2 diabetes mellitus.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328–357. - PubMed
    1. European Association for the Study of the Liver (EASL) European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388–1402. - PubMed
    1. Wong VW, Wong GL, Choi PC, Chan AW, Li MK, Chan HY, Chim AM, Yu J, Sung JJ, Chan HL. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut. 2010;59:969–974. - PubMed
    1. Pais R, Charlotte F, Fedchuk L, Bedossa P, Lebray P, Poynard T, Ratziu V LIDO Study Group. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol. 2013;59:550–556. - PubMed
    1. Vuppalanchi R, Chalasani N. Screening Strategies for Nonalcoholic Steatohepatitis in High-Risk Individuals: Trimming Away the Fat. Dig Dis Sci. 2016;61:1790–1792. - PubMed

MeSH terms